We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EKF Ekf Diagnostics Holdings Plc

-0.90 (-3.21%)
Last Updated: 12:00:20
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.90 -3.21% 27.10 27.10 28.90 27.10 27.00 27.00 5,836 12:00:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 66.64M -10.1M -0.0222 -12.21 123.29M

Ekf Diagnostics Share Discussion Threads

Showing 3301 to 3323 of 4775 messages
Chat Pages: Latest  143  142  141  140  139  138  137  136  135  134  133  132  Older
Can he provide this weeks winning lottery numbers too? These finance experts are just trying to look smart - with "trying" the operative word. I have no idea where price is going next and nor does anyone else
Justin Urquhart Stewart is forecasting a pullback on the shares whilest being supportive of the company, I think.
Edit/tweaks to the above post.

Plus, I forgot to mention that there is also recruitment for a 3rd shift in one of Amazons US labs, also known as the night shift or graveyard shift, which is usually associated with 24 hour operation.

wan...thank you for your very insightful comment.
Great article Hastings, many thanks. Good to see confirmation that Trellus "should go onto the market by the end of May", and that a fourth spin-off is on the cards for next year.
The best shares don't retrace. Which is why I buy breakouts otherwise you miss the very best ones
Nurdin...Whilst Mr Stewart for the Daily Mail clearly recognises the history of success from the management team over some years, he makes no reference to that in any detail. With perhaps good reason if you are hoping to buy in at a cheaper price!

As I said in several recent posts, there are indeed a number of reasons beyond the metrics (that indicate a full price) to be bullish on EKF. Some of these are well covered in Hastings write-up.

Furthermore, looking beyond the financial metrics that JUS is obviously relying on or indeed implying, how does one value the agreement and relationship with Mount Sinai? This agreement and relationship provides EKF with advanced access to innovative commercial opportunities and presents significant opportunity for EKF to collaborate on ground breaking medical technologies that can be spun off and proceed down the IPO route.

This has already resulted in shareholders benefiting from owning shares via a dividend in-specie in the spin off, Renalytix (price at IPO £1.21 per share, share price now circa £10) and now Verici (if you kept your Renalytix shares with a current share price of circa 60p and in which EKF have received 2,677,981 shares), with Trellus Health next in line for an IPO.

However, the management are aiming to replicate this process further with at least one investment and IPO per year. Not two a penny, as these things take time,
but if you were only focused on certain financial metrics (as perhaps JUS implies), then you wouldn't have been invested in EKF any earlier either to have benefited from what is arguably difficult to measure. And I would suggest that Mr Stewart has likewise been unable to measure this aspect either.........however, arguably it must surely be worth at least some form of premium to get such exposure?

The managements track record in terms of delivery (not just the IPO's) is very encouraging indeed, and JUS has at least 'tentatively' recognised that fact!

And this is before I get into EKF's close-knit relationship with their new private sector partner (believed to be Amazon) and who's logistical expertise and ambitions extend 'far beyond' testing just their own employees (and with over 1 million employees this on its own should not be underestimated).

cheers scorpio and Shanklin. .No doubt it will be marked up Monday morning but am hoping not by much.
Nurdin Earlier would have been cheaper but still think it is a buy. Certainly think JUS is unwise in waiting for a dip. Any upgrade RNS from here and the current level will be history.

NB. I first bought about 5% below current levels.

Never too late. This is a long term winner from a greater need for it has a track record of spinning off businesses.
Like this one but looks like I have left it too late !
It looks like JUSTIN URQUHART STEWART FOR THE DAILY MAIL, likes EKF, but he hopes he can buy it cheaper, but he clearly does not fully appreciate what else is under EKF's bonnet (nor appreciates who EKF's private partner is and how that relationship might evolve, or perhaps even hoping it's not actually revealed anytime soon).

Time will tell, but he might do well to read Hastings excellent and most recent coverage -

Whilst the huge level of success from its PrimeStore offering has been the key driver of EKF’s share price over the last year, there continues to be much more on offer here.

Full article -

The Daily Mail piece -
MR MONEY MAKER: EKF Diagnostics has the kit to give your portfolio a shot in the arm

PUBLISHED: 21:50, 9 April 2021

Any suggestions?

So I like to look for history of success from the team over some years. EKF Diagnostics certainly has this, but the price is quite full.

I would prefer to keep it on the watch list and wait for a pullback, which will be coming in the not too distant future.

Full story -

As I said previously, there are indeed other reasons to be bullish on EKF (more of which later), and thus in my view there will likely be plenty of investors in the wings hoping to buy before upgrades (given the current broker conservatism), or on any weakness. JUS is clearly one one of those, and to a degree, talking it down to help achieve that.

Importantly though, and as a consequence, any meaningful weakness (if it materialises) might be very short lived!

Thanks for the update Martin - great insight into interesting future potential developments. !

Meanwhile Novacyt shares crashed by 40% today after failing to extend their contract with the Dept of Health and also entering into a contractual dispute with them.

It's also very pleasing that the title of the thread is good for the foreseeable ;-)

EKF Diagnostics for income and growth - A healthy, reliable combination!

Thank you Hastings, another excellent and very informative write up, that also includes a number of very interesting and quite exciting insights.
Spoke with the CEO this morning and write up below for interest. Https://
Hi wan

Thank you for all that info.

Hopefully EKF or third parties pffering a service based on EKF kit, such as Amazon, will promote themselves well enough to get a big slice of this work. Would be disappointing were that not to happen.

Bizarre response from Grant Shapps on BBC Breakfast today where he was trying to magic down the current apparent £150 cost of PCR tests down to a lower level so that more people could go on holiday. He semed to have no clue beyond "competition" for why this would happen.

Presumably EKF's ability to not require the tests to be processed in higher level labs would help with this? But WDIK?

Most readers will already appreciate that EKF has a significant distribution agreement with Mckesson in the US. So, I found the following comments insightful and supports my previous comments on why 'partnering' and indeed deep and equitable relationships can be the preferred option -

6th April 2021
Look at the pandemic's effect on supply chain, with McKesson's Craig Dolan

McKesson was selected by the Centers for Disease Control and Prevention to be the centralized distributor for vaccines and ancillary supply kits.

Most hospitals planned to have months of supply of critical drugs in the early days of the pandemic.

"While we saw pandemic-induced buying in 2020, hospitals have learned lessons in how they treat COVID-19 and how they manage supplies moving forward," Dolan said. "Hospitals will apply new ways of forecasting in 2021 and beyond to ultimately strengthen the U.S. supply chain."

Over the last year, Dolan said he has spoken to customers to build stronger relationships. He and McKesson field accounts teams are now working with health systems to look at their medical spend, identify revenue recovery opportunities and advise hospitals on how to navigate.

Dolan anticipates hospitals will leverage scale with suppliers and apply new ways of forecasting supply in 2021 – all in the pursuit of a more transparent and equitable supply chain.

"We're advising customers to continue to work closely with suppliers for each issue they may be facing," he said. "Each group in the supply chain should be working together to solve problems. And while we are all eager to return to normal and less volatility, the eagerness to partner and deepen relationships will only benefit the supply chain moving forward."
Full story -

The following is 'confirmation' that my thoughts that the MyHealthChecked deal with Boots utilises EKF products, and possibly we have first sight of an EKF assembled 'test-kit' -

8. Hold the ShuttlePouchTM so that you have a clear view of the PrimeStore® MTM tube inside, visually check the white pad behind the tube for any signs of leakage such as discoloration or crystallisation. If there are signs of leakage do not remove the tube from the ShuttlePouch, seal the ShuttlePouch and do not proceed with the sample collection. Place the Shuttlepouch back inside the box, and dispose in your household waste. Please contact immediately and advise them of the barcode number on the damaged tube. If there are no signs of leakage, remove the tube of PrimeStore® MTM, place on a clean surface and proceed to section 9.

I note that I put the wrong link in yesterdays post (1710) re PrimeStore MTM use in the MHC PCR test kit -

I for one, shall certainly not be following the link provided in the above post!
Hi all, I have written an article on EKF for my website, looking at the recent results and opportunities for growth EKF has in the medium term. Available here: hxxps://
Bit of activity on the Open Orphan thread. Last night in a presentation regarding potential spin offs from the main company, CEO Cathal Friel referred to EKF and RENX in regard to the benefits of in specie dividends. Cited RENX Nasdaq listing and share price. Good to see the company being quoted as a model for how best to look after your shareholders
Chat Pages: Latest  143  142  141  140  139  138  137  136  135  134  133  132  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |